Clinical trials: FAP
Familial Adenomatous Polyposis, Colorectal Cancer
Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)
The goal of this research study is to test the first version of a website that will offer information and support for adolescents and young adults with FAP.
- Trial name
- NCT00525655
- Testing
- Web-Based Multimedia Intervention, Questionnaire
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Hereditary Transthyretin-mediated Amyloidosis With Polyneropathy, Pregnancy
TEGSEDI Pregnancy Surveillance Program
This is a worldwide safety surveillance study of pregnancy outcomes in women with hATTR-PN who may have been exposed or were not exposed to TEGSEDI prior to or during the pregnancy and of pediatric outcomes up to 1 year of age.
- Trial name
- NCT04270058
- Testing
- inotersen
- Volunteers
- 20 people
- Sponsor
- Akcea Therapeutics
Healthy Volunteers
A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers
A pharmacokinetic study in healthy volunteers to determine the relative bioavailability of three formulations of celecoxib to the approved formulation.
- Trial name
- NCT00813241
- Testing
- celecoxib reference formulation, celecoxib test formulation A1, celecoxib test formulation B2
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
PET/CT, FAPI
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
In this prospective study, the investigators will use integrated PET/CT with the agent 68Ga-FAPI and conventional imaging agent 18F-FDG to explore the application value of FAP-targeted molecular imaging in the diagnosis and…
- Conditions
- PET/CT, FAPI, Oral Cancer
- Trial name
- FAPI-OSCC (NCT05030597)
- Testing
- 68Ga-DOTA-FAPI, PET/CT, Participants receive baseline paired FDG and FAPI PET/CT. For resectable locally advanced cases receiving neoadjuvant therapy undergo follow-up FAPI PET imaging.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhongnan Hospital
Amyloidosis, Hereditary, Amyloidosis Cardiac
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substitution at position 122 (V122I) in the transthyretin (TTR) protein.
- Conditions
- Amyloidosis, Hereditary, Amyloidosis Cardiac, Amyloidosis, Familial, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
- Trial name
- NCT05489549
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of Texas Southwestern Medical Center
Cancer
Incidental Cancer in Familial Adenomatous Polyposis
Colectomy is life-saving in patients with familial adenomatous polyposis (FAP) because cancer development is inevitable in individuals with this disease.
- Trial name
- NCT05171426
- Where
- Turkey (Türkiye)
- Volunteers
- 55 people
- Sponsor
- Dr. Ersin Arslan Education and Training Hospital
Familial Adenomatous Polyposis
Niclosamide for Familial Adenomatous Polyposis
Familial adenomatous polyposis (FAP) leads to adenomas and eventual adenocarcinomas in colon and less frequently, duodenum. Chemopreventive strategies have been studied in FAP patients to delay the development of adenomas and…
- Trial name
- NCT04296851
- Testing
- Niclosamide
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Yonsei University
Advanced Solid Tumor
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
This is a single-center, single-arm clinical study to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-XT117 injection in patients with FAP-positive advanced solid tumors.
- Trial name
- NCT06197139
- Testing
- [177Lu]Lu-XT117
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xinlu Wang
Metastatic Colorectal Cancer
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
This is an open-label, multicenter, Phase Ib study to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) in the weekly (QW) and/or every 3 weeks (Q3W) regimens, safety, tolerability, PK…
- Trial name
- NCT04826003
- Testing
- RO7122290, Cibisatamab, Obinutuzumab
- Where
- 13 sites in Denmark, Netherlands and 3 more
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
The purpose of this study is to: Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients Characterize the safety and effectiveness of patisiran and…
- Trial name
- ConTTRibute (NCT04561518)
- Where
- 40 sites in United States, Brazil and 10 more
- Volunteers
- 1,500 people
- Sponsor
- Alnylam Pharmaceuticals
Amyloid Neuropathies, Transthyretin Amyloidosis
Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study
Familial amyloid neuropathies (FAP) are hereditary disease due to a mutation of the tranthyretin gene (TTR). These neuropathies are severe and life frightening.
- Trial name
- NCT03588468
- Testing
- Electrophysiological biomarkers, MRI biomarkers
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Transthyretin Amyloidosis, ATTR-CM
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes.
- Conditions
- Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
- Trial name
- MaesTTRo (NCT06465810)
- Testing
- Treatment of transthyretin (ATTR) amyloidosis in observational study setting
- Where
- 89 sites in United States, Canada and 4 more
- Volunteers
- 1,850 people
- Sponsor
- AstraZeneca
Amyloidosis
The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart
ATTRwt (also known as senile systemic, or senile cardiac amyloidosis) is a progressive heart disease, causing congestive heart failure.
- Trial name
- NCT02627820
- Testing
- Isis 420915/GSK 299872
- Sponsor
- Brigham and Women's Hospital
Familial Adenomatous Polyposis
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Primary Objective: To determine whether celecoxib downregulates GATA-6 expression to upregulate 15-LOX-1 expression and induce apoptosis in human rectal tumors, researchers will measure GATA-6 and 15-LOX-1 expression, 13-S-HODE…
- Trial name
- NCT00503035
- Testing
- Celecoxib, Colonoscopy Biopsy
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Familial Adenomatous Polyposis
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
This is a multicenter, two-part trial in participants with FAP.
- Trial name
- TUPELO (NCT05552755)
- Testing
- REC-4881
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Patients with Advanced Metastatic FAP-Positive Tumors
177Lu-JH04 in Patients with FAP-Positive Tumors
This is a pilot study to assess the dosimetry, toxicity and response of 177Lu-JH04, a new FAP-targeted radiopharmaceutical, in patients with FAP-Positive Tumors.
- Trial name
- NCT06636617
- Testing
- 3.70 GBq (100 mCi) of 177Lu-JH04, 5.55 GBq (150 mCi) of 177Lu-JH04, 7.40 GBq (200 mCi) of 177Lu-JH04
- Where
- China
- Volunteers
- 9 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Cardiomyopathies, Primary
Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy
18F-Flutemetamol (Vizamyl) is a radioactive diagnostic agent indicated and FDA-approved for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive…
- Trial name
- NCT05374564
- Testing
- (18F)Flutemetamol
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Yale University
Transthyretin Amyloidosis With Cardiomyopathy
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
The purpose of this study is to: Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care Describe treatment…
- Trial name
- DemonsTTRate (NCT07358078)
- Where
- 27 sites in United States, Germany and 1 more
- Volunteers
- 2,000 people
- Sponsor
- Alnylam Pharmaceuticals
Lung Cancer, Atrial Fibrillation
PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer
The aim of this study is to assess whether prophylactic treatment with metoprolol or losartan is able to reduce the incidence of atrial fibrillation (AF) in patients undergoing thoracic surgery for lung cancer, showing elevated…
- Trial name
- PRESAGE (NCT01281787)
- Testing
- Metoprolol, Losartan
- Where
- Italy
- Volunteers
- 320 people
- Sponsor
- European Institute of Oncology
Solid Tumors
A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors
To explore the safety, tolerability, initial efficacy, pharmacokinetic profile and radiation dosimetry of lutetium [177Lu]-FAP-75 in the treatment of patients with advanced solid tumors.
- Trial name
- NCT06553846
- Testing
- Lutetium [177Lu]-FAP-75
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University